ATE536185T1 - Verfahren zur abschwächung von reaktionen auf hautreizende mittel - Google Patents
Verfahren zur abschwächung von reaktionen auf hautreizende mittelInfo
- Publication number
- ATE536185T1 ATE536185T1 AT02723627T AT02723627T ATE536185T1 AT E536185 T1 ATE536185 T1 AT E536185T1 AT 02723627 T AT02723627 T AT 02723627T AT 02723627 T AT02723627 T AT 02723627T AT E536185 T1 ATE536185 T1 AT E536185T1
- Authority
- AT
- Austria
- Prior art keywords
- immune responses
- compositions
- cd1d
- attenuate
- reactions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27883701P | 2001-03-26 | 2001-03-26 | |
PCT/US2002/009378 WO2002076401A2 (en) | 2001-03-26 | 2002-03-26 | Method of attenuating reactions to skin irritants |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE536185T1 true ATE536185T1 (de) | 2011-12-15 |
Family
ID=23066584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02723627T ATE536185T1 (de) | 2001-03-26 | 2002-03-26 | Verfahren zur abschwächung von reaktionen auf hautreizende mittel |
Country Status (6)
Country | Link |
---|---|
US (4) | US7419958B2 (de) |
EP (1) | EP1372668B1 (de) |
AT (1) | ATE536185T1 (de) |
AU (1) | AU2002254396A1 (de) |
CA (1) | CA2441893C (de) |
WO (1) | WO2002076401A2 (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010051156A1 (en) * | 2000-04-28 | 2001-12-13 | Defu Zeng | Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
AU2002254396A1 (en) * | 2001-03-26 | 2002-10-08 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
CN1780603A (zh) * | 2002-08-27 | 2006-05-31 | 雀巢制品公司 | 预防或治疗上皮组织损伤或毛发脱落 |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
EP1567113A4 (de) * | 2002-10-24 | 2006-11-08 | G & R Pharmaceuticals Llc | Antimykotische formulierungen |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
AU2003279493B2 (en) | 2002-10-25 | 2009-08-20 | Foamix Pharmaceuticals Ltd. | Cosmetic and pharmaceutical foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
JP5254616B2 (ja) | 2004-09-13 | 2013-08-07 | クロノ セラピューティクス、インコーポレイテッド | 生物学的同調性(biosynchronous)経皮的薬物送達 |
CN101031307B (zh) * | 2004-11-02 | 2012-09-05 | 小利兰斯坦福大学托管委员会 | 抑制nkt细胞的制药用途 |
US20070042026A1 (en) * | 2005-03-17 | 2007-02-22 | Wille John J | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions |
GB0510463D0 (en) * | 2005-05-23 | 2005-06-29 | Britania Pharmaceuticals Ltd | Improvements in or relating to organic materials |
WO2006127905A2 (en) | 2005-05-24 | 2006-11-30 | Chrono Therapeutics, Inc. | Portable drug delivery device |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
WO2008100912A1 (en) * | 2007-02-12 | 2008-08-21 | The General Hospital Corporation | Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists |
US8012484B2 (en) * | 2007-04-12 | 2011-09-06 | University Of Virginia Patent Foundation | Method of treating ischemia reperfusion injury by inhibiting NKT cell activity |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009090495A2 (en) | 2007-12-07 | 2009-07-23 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
EP2242476A2 (de) | 2008-01-14 | 2010-10-27 | Foamix Ltd. | Aufschäumbare pharmazeutische poloxamer-zusammensetzungen mit wirkstoffen und/oder therapeutischen zellen und verwendungen |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
MX359879B (es) | 2009-10-02 | 2018-10-12 | Foamix Pharmaceuticals Ltd | Composiciones tópicas de tetraciclina. |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
EP3616701A1 (de) | 2011-06-24 | 2020-03-04 | GRI Bio, Inc. | Vorbeugung und behandlung entzündlicher erkrankungen |
US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
US20140221320A1 (en) * | 2011-07-08 | 2014-08-07 | The Research Foundation For The State University Of New York | Topical minocycline ointment for suppression of allergic skin responses |
AU2013271836B2 (en) * | 2012-06-05 | 2018-03-01 | Olatec Therapeutics Llc | Method for treating skin inflammatory diseases |
US8663177B1 (en) * | 2012-09-28 | 2014-03-04 | Anal-Gesic LLC | Medication delivery, dosing and safety devices, systems and kits |
EP2906576B1 (de) | 2012-10-12 | 2019-09-11 | The Brigham and Women's Hospital, Inc. | Glycosphingolipide und verfahren zur verwendung davon |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
JP2018511127A (ja) | 2015-03-12 | 2018-04-19 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 渇望入力及び支援システム |
CA2978573A1 (en) | 2016-09-08 | 2018-03-08 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
JP2020503950A (ja) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 経皮薬剤送達の装置及び方法 |
US20190083325A1 (en) * | 2017-09-21 | 2019-03-21 | The Procter & Gamble Company | Absorbent Article |
WO2019232077A1 (en) | 2018-05-29 | 2019-12-05 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
EP3975958A1 (de) | 2019-05-31 | 2022-04-06 | The Procter & Gamble Company | Verfahren und vorrichtung zum verbinden von elastischen teilen unter spannung auf einen vorschubträger |
JP2023523750A (ja) | 2020-05-05 | 2023-06-07 | ザ プロクター アンド ギャンブル カンパニー | 改良された弾性パネルを含む吸収性物品 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0174912A3 (de) * | 1984-09-13 | 1986-06-04 | Ciba-Geigy Ag | Phosphorverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung |
JPS63255213A (ja) | 1987-04-13 | 1988-10-21 | Kanebo Ltd | 養毛化粧料 |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
JPH0317020A (ja) | 1989-06-14 | 1991-01-25 | Nippon Koutai Kenkyusho:Kk | 抗hiv剤 |
US5776429A (en) * | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US5565207A (en) * | 1990-09-19 | 1996-10-15 | Pola Kasei Kogyo Kabushiki Kaisha | Scalp moisturizer and external skin preparation |
US5602183A (en) | 1991-03-01 | 1997-02-11 | Warner-Lambert Company | Dermatological wound healing compositions and methods for preparing and using same |
WO1992017189A1 (en) | 1991-03-29 | 1992-10-15 | The Regents Of The University Of California | Gangliosides with immunosuppressive activity |
US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US5936076A (en) * | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
JP3231079B2 (ja) | 1992-05-29 | 2001-11-19 | ポーラ化成工業株式会社 | 消炎鎮痛外用剤 |
US5679347A (en) | 1992-12-10 | 1997-10-21 | Brigham And Women's Hospital | Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods |
US7063844B2 (en) | 1992-12-10 | 2006-06-20 | The Brigham And Women's Hospital, Inc. | Presentation of hydrophobic antigens to T-cells by CD1 molecules |
DE69433115T2 (de) | 1993-06-21 | 2004-04-01 | Brigham And Women's Hospital, Boston | Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
US5459037A (en) | 1993-11-12 | 1995-10-17 | The Scripps Research Institute | Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations |
US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
JP2896321B2 (ja) | 1994-10-27 | 1999-05-31 | 鐘紡株式会社 | β−グルコセレブロシダーゼの活性化方法 |
US5945409A (en) * | 1995-03-10 | 1999-08-31 | Wilson T. Crandall | Topical moisturizing composition and method |
US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
US5738856A (en) * | 1995-11-03 | 1998-04-14 | Ocular Research Of Boston, Inc. | Skin care preparation and method |
FR2742054B1 (fr) * | 1995-12-06 | 1998-01-09 | Synthelabo | Compositions pharmaceutiques contenant un agent anti-inflammatoire et des ceramides vegetales |
US5776683A (en) | 1996-07-11 | 1998-07-07 | California Pacific Medical Center | Methods for identifying genes amplified in cancer cells |
NZ336539A (en) * | 1996-10-15 | 2000-09-29 | Liposome Co Inc | Peptide-lipid conjugates, liposomes and liposomal drug delivery |
KR100527950B1 (ko) | 1997-04-10 | 2005-11-09 | 기린 비루 가부시키가이샤 | 알파-글리코실세라미드를 함유하는 엔케이티 세포활성화제 |
US6063387A (en) * | 1997-04-17 | 2000-05-16 | Elizabeth Arden Co., Division Of Conopco, Inc. | Anhydrous cosmetic composition with ceramides for firming skin |
FR2765877B1 (fr) * | 1997-07-10 | 1999-09-10 | Oreal | Composition comprenant une dispersion aqueuse de vesicules lipidiques a base de carbamates a chaine cholesteryle, utilisation notamment en cosmetique et nouveaux composes |
JP2001515868A (ja) | 1997-09-12 | 2001-09-25 | ブライハム アンド ウイメンズ ホスピタル | Cd1制限免疫応答のための合成抗原 |
TW575420B (en) | 1997-09-22 | 2004-02-11 | Kirin Brewery | Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides |
JP2001510487A (ja) | 1997-12-05 | 2001-07-31 | デーエスエム ナムローゼ フェンノートシャップ | 遊離スフィンゴイド塩基及びセラミドの組合せを含む組成物並びにその使用 |
EP1049477A1 (de) | 1997-12-30 | 2000-11-08 | A+ Science Invest AB | Galactosylceramide, glucosylceramide, lactosylceramide, und spezifische fänger für diese zur verwendung in der prophylaxe oder therapie der prädiabetes, diabetes und/oder damit zusammenhängender komplikationen |
US6610835B1 (en) | 1998-02-12 | 2003-08-26 | Emory University | Sphingolipid derivatives and their methods of use |
US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
JPH11302155A (ja) | 1998-04-24 | 1999-11-02 | La Shinshia Kk | アトピー性皮膚炎のための皮膚外用剤 |
AU748565B2 (en) | 1998-06-23 | 2002-06-06 | Board Of Trustees Of The Leland Stanford Junior University | Adjuvant therapy |
ATE339452T1 (de) | 1998-07-09 | 2006-10-15 | Brian J Nickoloff | Methode zur behandlung von krankheiten durch veränderung der wechselwirkung zwischen natural killer rezeptoren auf t-zellen mit ihren jeweiligen liganden |
DE19841794A1 (de) | 1998-09-12 | 2000-03-16 | Beiersdorf Ag | Kombinationen von Antiadhäsiva (Ceramide und Sphingosine und Derivate) und Mikrobiziden |
JP2000264825A (ja) | 1999-03-17 | 2000-09-26 | Fancl Corp | 乳化組成物 |
JP2000264829A (ja) | 1999-03-17 | 2000-09-26 | Fancl Corp | 乳化組成物 |
US20010051156A1 (en) | 2000-04-28 | 2001-12-13 | Defu Zeng | Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions |
AU2002213588A1 (en) | 2000-06-05 | 2001-12-17 | The Brigham And Women's Hospital, Inc. | Soluble cd1 compositions and uses thereof |
AU2001262697A1 (en) | 2000-06-06 | 2001-12-17 | Kirin Beer Kabushiki Kaisha | Method of amplifying natural killer t cells |
ES2389645T3 (es) | 2000-06-19 | 2012-10-30 | Beth Israel Deaconess Medical Center | Composiciones y métodos de anticuerpos monoclonales y policlonales específicos para subpoblaciones de linfocitos T |
WO2001098317A2 (en) | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
JP3986957B2 (ja) | 2000-08-18 | 2007-10-03 | 三菱電機株式会社 | ランプ用トランス |
DE10046658A1 (de) | 2000-09-20 | 2002-04-04 | Bosch Gmbh Robert | Induktiver Übertrager und ein Verfahren zu dessen Herstellung |
US6372236B1 (en) * | 2000-10-18 | 2002-04-16 | Doosan Corporation | Cream composition for skin care |
DE60131456T2 (de) * | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
IL140537A0 (en) | 2000-12-25 | 2002-02-10 | Hadasit Med Res Service | Educated nk t cells and their uses in the treatment of immune-related disorders |
AU2002254396A1 (en) | 2001-03-26 | 2002-10-08 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
US6662434B2 (en) | 2001-04-03 | 2003-12-16 | General Electric Company | Method and apparatus for magnetizing a permanent magnet |
US8178098B2 (en) * | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
JP4334233B2 (ja) | 2001-04-11 | 2009-09-30 | アセロジエニクス・インコーポレイテツド | プロブコールモノエステルによって血漿hdlコレステロールレベルを上昇させ、hdlの機能性を改善するための方法 |
US20020171538A1 (en) | 2001-05-15 | 2002-11-21 | Kuo-Hsin Su | Vehicle motion detector and control device arrangement |
US20020171557A1 (en) | 2001-05-18 | 2002-11-21 | Wegener William E. | Security electronic system |
WO2003009812A2 (en) * | 2001-07-25 | 2003-02-06 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
US20030147865A1 (en) | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
AU2003234443A1 (en) | 2002-05-01 | 2003-11-17 | Beth Israel Deaconess Medical Center | Use of anti-cd1 antibodies for the modulation of immune responses |
CA2493690C (en) | 2002-06-13 | 2011-11-08 | New York University | Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases |
ES2384439T3 (es) | 2002-06-14 | 2012-07-04 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Procedimientos de tratamiento y prevención de colitis que se implican IL-13 y células NK-T |
US7368142B2 (en) | 2002-08-01 | 2008-05-06 | Renew Life Formulas, Inc. | Natural sweetener |
CN1780603A (zh) | 2002-08-27 | 2006-05-31 | 雀巢制品公司 | 预防或治疗上皮组织损伤或毛发脱落 |
WO2004026318A1 (ja) | 2002-09-20 | 2004-04-01 | Kirin Beer Kabushiki Kaisha | α-グリコシルセラミドを有効成分とするC型肝炎ウイルス抑制剤 |
WO2004028475A2 (en) | 2002-09-27 | 2004-04-08 | Biomira, Inc. | Glycosylceramide analogues |
WO2005032462A2 (en) | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
US9717754B2 (en) | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
US20040171522A1 (en) | 2003-02-27 | 2004-09-02 | Yaron Ilan | Regulation of immune responses by manipulation of intermediary metabolite levels |
US20050032210A1 (en) | 2003-03-18 | 2005-02-10 | Kirin Beer Kabushiki Kaisha | Method of preparing immuno-regulatory dendritic cells and the use thereof |
US20040235162A1 (en) | 2003-03-18 | 2004-11-25 | Kirin Beer Kabushiki Kaisha | Method of preparing immunoregulatory dendritic cells and the use thereof |
CA2519568C (en) | 2003-03-20 | 2012-01-03 | Brigham Young University | 6"-amino-6"-deoxygalactosylceramides |
WO2004084874A2 (en) | 2003-03-24 | 2004-10-07 | Brigham And Women's Hospital, Inc. | Mtp inhibitors for inhibiting inflammation |
WO2005014008A2 (en) | 2003-07-17 | 2005-02-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Treatment of disorders associated with natural killer t cells |
KR101215808B1 (ko) * | 2004-06-11 | 2012-12-26 | 도꾸리쯔교세이호징 리가가쿠 겐큐소 | 조절성 세포 리간드를 리포좀에 함유시켜 이루어지는 의약 |
WO2006002132A2 (en) | 2004-06-21 | 2006-01-05 | Exxonmobil Chemical Patents Inc. | Olefin polymerization process |
CN101031307B (zh) | 2004-11-02 | 2012-09-05 | 小利兰斯坦福大学托管委员会 | 抑制nkt细胞的制药用途 |
US20080241174A1 (en) | 2005-03-18 | 2008-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Production And Therapeutic Uses Of Th1-Like Regulatory T Cells |
JP5331049B2 (ja) | 2010-04-16 | 2013-10-30 | 株式会社日立製作所 | 回転電機の回転子挿入装置および挿入方法 |
-
2002
- 2002-03-26 AU AU2002254396A patent/AU2002254396A1/en not_active Abandoned
- 2002-03-26 US US10/106,901 patent/US7419958B2/en not_active Expired - Fee Related
- 2002-03-26 CA CA2441893A patent/CA2441893C/en not_active Expired - Fee Related
- 2002-03-26 EP EP02723627A patent/EP1372668B1/de not_active Expired - Lifetime
- 2002-03-26 AT AT02723627T patent/ATE536185T1/de active
- 2002-03-26 WO PCT/US2002/009378 patent/WO2002076401A2/en not_active Application Discontinuation
-
2008
- 2008-06-25 US US12/146,386 patent/US20080260680A1/en not_active Abandoned
-
2013
- 2013-10-25 US US14/063,356 patent/US20140286949A1/en not_active Abandoned
-
2015
- 2015-07-17 US US14/802,893 patent/US10226476B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2441893A1 (en) | 2002-10-03 |
US20080260680A1 (en) | 2008-10-23 |
AU2002254396A1 (en) | 2002-10-08 |
US20020165170A1 (en) | 2002-11-07 |
CA2441893C (en) | 2015-01-20 |
EP1372668A2 (de) | 2004-01-02 |
US7419958B2 (en) | 2008-09-02 |
US10226476B2 (en) | 2019-03-12 |
EP1372668B1 (de) | 2011-12-07 |
WO2002076401A3 (en) | 2003-02-27 |
US20140286949A1 (en) | 2014-09-25 |
EP1372668A4 (de) | 2007-07-25 |
WO2002076401A2 (en) | 2002-10-03 |
US20160074423A1 (en) | 2016-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE536185T1 (de) | Verfahren zur abschwächung von reaktionen auf hautreizende mittel | |
BRPI0407993A (pt) | inibidores de p38 e métodos para uso dos mesmos | |
EP1478371A4 (de) | Verfahren und produkte zur verbesserung der immunantworten mit imidazochinolin-verbindungen | |
EP0930064A3 (de) | Balneologische Badezusätze, insbesondere in Form einer Brausetablette, Verfahren zu ihrer Herstellung und ihre Verwendung | |
HUP0102899A2 (hu) | Eljárás gyulladásgátló, különösen fertőtlenítő hatású és/vagy sebgyógyulást elősegítő szerek alsó légutakba történő beadására szolgáló készítmények előállítására | |
ATE443523T1 (de) | Verfahren zur behandlung von gelenkentzündung, schmerzen und mobilitätsverlust | |
ES2135470T3 (es) | Composiciones farmaceuticas y metodos que usan ibobutiramida para tratar trastornos de betaglobina. | |
PT781281E (pt) | Derivados de beta-carbolina agonistas da melatonina seu processo de preparacao e sua utilizacao a titulo de medicamento | |
DE3752007T2 (de) | Mittel zur Entziehung von Endprodukten der fortgeschrittenen Glycosylation | |
DK0759740T3 (da) | Anvendelse af laminarin og oligosaccharider afledt af laminarin inden for kosmetologien og til fremstilling af et medikament beregnet til behandling af huden | |
RU95103892A (ru) | Композиция топического нанесения для стимулирования роста волос и/или замедления их выпадения, способ косметического лечения волос, применение производного альфа -пирона для получения композиции | |
DK461689D0 (da) | Anvendelse af aktive stoffer med seritoninagonistisk virkning til fremstilling af laegemidler med apoplexia cerebri | |
CA2182030A1 (fr) | Utilisation d'un antagoniste de bradykinine dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue | |
FR2744452B1 (fr) | Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations | |
ATE77230T1 (de) | Melatoninhaltige mittel sowie deren verwendungen. | |
ATE318610T1 (de) | Orale zusammensetzungen zur behandlung von kopfhauterkrankungen | |
BR0211936A (pt) | Uso de glicosamina e de um inibidor seletivo para ciclooxigenase-2, ou de pró-droga dos mesmos, na fabricação de um medicamento, bem como composição farmacêutica e kit compreendendo os mesmos | |
MXPA03011622A (es) | Uso de glicoproteina para el tratamiento y re-epitelizacion de heridas. | |
BR9706889A (pt) | Uso de extratos de ginkgo biloba para a preparação de composições farmacêuticas e processo de tratamento cosmético usando um extrato de ginkgo biloba | |
DE60129606D1 (de) | Mittel und verfahren zur vorbeugung von durch chemotherapie ausgelöster alopezie | |
DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
ATE555787T1 (de) | Behandlungseffekte von überschüssigen reaktiven sauerstoffspezies | |
JP2004514689A (ja) | 表面血流刺激性スキンクリーム | |
HUP0204180A2 (hu) | Külsőleges készítmény és alkalmazása allergiás dermatitisz kezelésére | |
BG105924A (en) | Composition for the treatment of psoriasis |